489 related articles for article (PubMed ID: 26500646)
21. Radiotherapy, PARP Inhibition, and Immune-Checkpoint Blockade: A Triad to Overcome the Double-Edged Effects of Each Single Player.
Rosado MM; Pioli C
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831435
[TBL] [Abstract][Full Text] [Related]
22. Combinations of immunotherapy and radiation in cancer therapy.
Vatner RE; Cooper BT; Vanpouille-Box C; Demaria S; Formenti SC
Front Oncol; 2014; 4():325. PubMed ID: 25506582
[TBL] [Abstract][Full Text] [Related]
23. Radiotherapy as a Backbone for Novel Concepts in Cancer Immunotherapy.
Kabiljo J; Harpain F; Carotta S; Bergmann M
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31905723
[TBL] [Abstract][Full Text] [Related]
24. The rationale for including immune checkpoint inhibition into multimodal primary treatment concepts of head and neck cancer.
Tinhofer I; Budach V; Jöhrens K; Keilholz U
Cancers Head Neck; 2016; 1():8. PubMed ID: 31093338
[TBL] [Abstract][Full Text] [Related]
25. Enhance the Immune Checkpoint Inhibitors Efficacy with Radiotherapy Induced Immunogenic Cell Death: A Comprehensive Review and Latest Developments.
Procureur A; Simonaggio A; Bibault JE; Oudard S; Vano YA
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33567530
[TBL] [Abstract][Full Text] [Related]
26. Immuno-oncology: Allying forces of radio- and immuno-therapy to enhance cancer cell killing.
Bernier J
Crit Rev Oncol Hematol; 2016 Dec; 108():97-108. PubMed ID: 27931845
[TBL] [Abstract][Full Text] [Related]
27. Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and preclinical experiences.
Brix N; Tiefenthaller A; Anders H; Belka C; Lauber K
Immunol Rev; 2017 Nov; 280(1):249-279. PubMed ID: 29027221
[TBL] [Abstract][Full Text] [Related]
28. Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy.
Gaipl US; Multhoff G; Scheithauer H; Lauber K; Hehlgans S; Frey B; Rödel F
Immunotherapy; 2014; 6(5):597-610. PubMed ID: 24896628
[TBL] [Abstract][Full Text] [Related]
29. High versus low dose irradiation for tumor immune reprogramming.
Ochoa de Olza M; Bourhis J; Irving M; Coukos G; Herrera FG
Curr Opin Biotechnol; 2020 Oct; 65():268-283. PubMed ID: 32882511
[TBL] [Abstract][Full Text] [Related]
30. Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model.
Wu L; Wu MO; De la Maza L; Yun Z; Yu J; Zhao Y; Cho J; de Perrot M
Oncotarget; 2015 May; 6(14):12468-80. PubMed ID: 25980578
[TBL] [Abstract][Full Text] [Related]
31. Immune modulatory roles of radioimmunotherapy: biological principles and clinical prospects.
Wang X; Wang Y; Zhang Y; Shi H; Liu K; Wang F; Wang Y; Chen H; Shi Y; Wang R
Front Immunol; 2024; 15():1357101. PubMed ID: 38449871
[TBL] [Abstract][Full Text] [Related]
32. Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential.
Frey B; Stache C; Rubner Y; Werthmöller N; Schulz K; Sieber R; Semrau S; Rödel F; Fietkau R; Gaipl US
J Immunotoxicol; 2012; 9(3):301-13. PubMed ID: 22800185
[TBL] [Abstract][Full Text] [Related]
33. Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation.
Buchwald ZS; Wynne J; Nasti TH; Zhu S; Mourad WF; Yan W; Gupta S; Khleif SN; Khan MK
Front Oncol; 2018; 8():612. PubMed ID: 30619752
[TBL] [Abstract][Full Text] [Related]
34. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
35. The Abscopal Effect: Could a Phenomenon Described Decades Ago Become Key to Enhancing the Response to Immune Therapies in Breast Cancer?
Kolberg HC; Hoffmann O; Baumann R
Breast Care (Basel); 2020 Oct; 15(5):443-449. PubMed ID: 33223988
[TBL] [Abstract][Full Text] [Related]
36. Combination of radiotherapy and immune treatment: First clinical data.
De Ruysscher D
Cancer Radiother; 2018 Oct; 22(6-7):564-566. PubMed ID: 30170788
[TBL] [Abstract][Full Text] [Related]
37. Radiotherapy combined with nano-biomaterials for cancer radio-immunotherapy.
Dong Q; Xue T; Yan H; Liu F; Liu R; Zhang K; Chong Y; Du J; Zhang H
J Nanobiotechnology; 2023 Oct; 21(1):395. PubMed ID: 37899463
[TBL] [Abstract][Full Text] [Related]
38. [Cancer, radiotherapy and immune system].
Nesseler JP; Peiffert D; Vogin G; Nickers P
Cancer Radiother; 2017 Jun; 21(4):307-315. PubMed ID: 28501459
[TBL] [Abstract][Full Text] [Related]
39. Combination of ionising radiation with hyperthermia increases the immunogenic potential of B16-F10 melanoma cells in vitro and in vivo.
Werthmöller N; Frey B; Rückert M; Lotter M; Fietkau R; Gaipl US
Int J Hyperthermia; 2016; 32(1):23-30. PubMed ID: 26754406
[TBL] [Abstract][Full Text] [Related]
40. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
